MAOIs, SSRIs, and Psychedelics
<p>Millions of people in the world suffer from depression and anxiety of various causes and manifestations [<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02143-7/fulltext" rel="noopener ugc nofollow" target="_blank">1</a>]. Since the mid-20th century, biological interventions, typically in the form of pharmaceutical drugs, have been introduced to help treat these issues and improve people’s lives. A key target of these drugs is the neuromodulator systems within the brain and central nervous system. <a href="https://en.wikipedia.org/wiki/Neuromodulation" rel="noopener ugc nofollow" target="_blank">Neuromodulators</a> are a subclass of neurotransmitters which act in a more global way within the nervous system. The neuromodulators that are typically targeted as part of therapeutic treatments include three names most of us are familiar with in one way or another: dopamine, serotonin, and norepinephrine. While almost all drugs approved to treat depression and anxiety disorders act on these neuromodulator systems, they do so in very different ways, with different levels of effectiveness and side-effects as a result. </p>
<p><a href="https://awjuliani.medium.com/maois-ssris-and-psychedelics-9175fe1aac3f"><strong>Website</strong></a></p>